Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

AGE: 18 years and older
GENDER: All
TYPE: Drug Study (pembrolizumab)
HEALTHY PARTICIPANTS: No
CONDITION: Recurrent Glioblastoma

Study Purpose

The purpose of this study is to test the side effects and efficacy of using Laser Interstitial Thermotherapy (LITT) combined with the Pembrolizumab. LITT is a minimally invasive surgical technique that uses a laser to heat brain tumors. Pembrolizumab is an investigational (experimental) drug that works by helping participants' immune system work correctly to detect and fight cancer cells. Pembrolizumab is experimental because it is not approved by the Food and Drug Administration (FDA), for this use, though it is approved to treat other cancers.

Who Can Participate

Patients 18 years and older with a diagnosis of glioblastoma or gliosarcoma may be eligible for this study.

Learn More About This Research Study

For more information, please contact Christopher Murphy, RN, the study coordinator at 216-983-3021 or contact us using the online form below.

To learn more about this study, please fill out the form below to request more information.
XXX-XXX-XXXX